TW201925193A - 多巴胺－β－羥化酶抑制劑 - Google Patents

多巴胺－β－羥化酶抑制劑 Download PDF

Info

Publication number
TW201925193A
TW201925193A TW107143059A TW107143059A TW201925193A TW 201925193 A TW201925193 A TW 201925193A TW 107143059 A TW107143059 A TW 107143059A TW 107143059 A TW107143059 A TW 107143059A TW 201925193 A TW201925193 A TW 201925193A
Authority
TW
Taiwan
Prior art keywords
methyl
thione
group
pyrrolo
imidazol
Prior art date
Application number
TW107143059A
Other languages
English (en)
Chinese (zh)
Inventor
拉斯洛 齊思
亞歷山大 別列亞夫
蒂諾 羅西
佩德羅 萊爾帕爾馬
帕特里西奧 蘇亞雷斯達席爾瓦
瑞 賓托
法蘭西斯 卡登納
Original Assignee
葡萄牙商比亞爾 波特拉公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1720189.8A external-priority patent/GB201720189D0/en
Priority claimed from GBGB1804439.6A external-priority patent/GB201804439D0/en
Application filed by 葡萄牙商比亞爾 波特拉公司 filed Critical 葡萄牙商比亞爾 波特拉公司
Publication of TW201925193A publication Critical patent/TW201925193A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW107143059A 2017-12-04 2018-11-30 多巴胺－β－羥化酶抑制劑 TW201925193A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1720189.8A GB201720189D0 (en) 2017-12-04 2017-12-04 Dopamine-B-hydroxylase inhibitors
??1720189.8 2017-12-04
??1804439.6 2018-03-20
GBGB1804439.6A GB201804439D0 (en) 2018-03-20 2018-03-20 Dopamin-b-hydroxylase inhibitors

Publications (1)

Publication Number Publication Date
TW201925193A true TW201925193A (zh) 2019-07-01

Family

ID=65012066

Family Applications (1)

Application Number Title Priority Date Filing Date
TW107143059A TW201925193A (zh) 2017-12-04 2018-11-30 多巴胺－β－羥化酶抑制劑

Country Status (16)

Country Link
US (2) US11434242B2 (https=)
EP (1) EP3720856A1 (https=)
JP (1) JP7167155B2 (https=)
KR (1) KR20200096584A (https=)
CN (1) CN111479812A (https=)
AU (1) AU2018379646A1 (https=)
BR (1) BR112020010216A2 (https=)
CA (1) CA3082337A1 (https=)
CL (1) CL2020001461A1 (https=)
IL (1) IL274550B2 (https=)
MX (1) MX2020005864A (https=)
PH (1) PH12020500542A1 (https=)
RU (1) RU2020121820A (https=)
SG (1) SG11202004231YA (https=)
TW (1) TW201925193A (https=)
WO (1) WO2019112457A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111479812A (zh) 2017-12-04 2020-07-31 巴尔-波特拉及康邦亚股份有限公司 多巴胺-b-羟化酶抑制剂
GB201908044D0 (en) 2019-06-05 2019-07-17 Bial Portela & Ca Sa Dopamine-B-Hydroxylase inhibitors
US20250122171A1 (en) * 2023-09-20 2025-04-17 Deep Apple Therapeutics, Inc. Substituted Amine Compounds, Compositions and Methods of Use
CN120383599A (zh) * 2024-01-29 2025-07-29 上海深势唯思科技有限责任公司 芳基杂环类Kv1.3抑制剂及其制备方法和用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3647790A (en) 1969-04-08 1972-03-07 American Home Prod Ouinoxalinyl-oxazolidines and -oxazines
FR2449689A1 (fr) 1979-02-20 1980-09-19 Logeais Labor Jacques Nouveaux derives condenses de pyrrolidine ou de piperidine, leur procede de preparation et leurs applications en therapeutique
US4628059A (en) 1985-10-31 1986-12-09 Smithklein Beckman Corporation Dopamine-β-hydroxylase inhibitors
WO1995029165A2 (en) 1994-04-26 1995-11-02 Syntex (U.S.A.) Inc. Benzocycloalkylaz0lethione derivatives as dopamin beta-hydroxylase inhibitors
US6482982B1 (en) 2001-03-09 2002-11-19 University Of Sciences Of Philadelphia Halogenated antituberculosis agents
IL143379A (en) * 2001-05-24 2013-11-28 Yissum Res Dev Co Oligonucleotide against human ache isoform r and its uses
US7125904B2 (en) 2002-10-11 2006-10-24 Portela & C.A., S.A. Peripherally-selective inhibitors of dopamine-β-hydroxylase and method of their preparation
WO2008085008A1 (en) 2007-01-11 2008-07-17 Mogam Biotechnology Research Institute T-cell inhibiting compounds and their use for the treatment of t-cell-mediated diseases
GB0708818D0 (en) * 2007-05-08 2007-06-13 Portela & Ca Sa Compounds
JP2010534676A (ja) 2007-07-23 2010-11-11 シノシア・セラピューティクス 心的外傷後ストレス障害の治療
US8110578B2 (en) * 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
WO2014127350A1 (en) 2013-02-18 2014-08-21 The Scripps Research Institute Modulators of vasopressin receptors with therapeutic potential
JOP20190050A1 (ar) 2016-09-23 2019-03-20 Bial Portela & C? S A مثبطات دوبامين-b-هيدروكسيلاز تخترق حاجز المخ الدموي
CN111479812A (zh) 2017-12-04 2020-07-31 巴尔-波特拉及康邦亚股份有限公司 多巴胺-b-羟化酶抑制剂

Also Published As

Publication number Publication date
IL274550B2 (en) 2023-06-01
US11434242B2 (en) 2022-09-06
JP7167155B2 (ja) 2022-11-08
WO2019112457A1 (en) 2019-06-13
CN111479812A (zh) 2020-07-31
IL274550A (en) 2020-06-30
MX2020005864A (es) 2020-09-09
PH12020500542A1 (en) 2021-01-25
US20210171528A1 (en) 2021-06-10
SG11202004231YA (en) 2020-06-29
KR20200096584A (ko) 2020-08-12
BR112020010216A2 (pt) 2020-09-15
JP2021505568A (ja) 2021-02-18
CA3082337A1 (en) 2019-06-13
CL2020001461A1 (es) 2020-10-16
AU2018379646A1 (en) 2020-06-11
US20230138795A1 (en) 2023-05-04
RU2020121820A (ru) 2022-01-10
EP3720856A1 (en) 2020-10-14

Similar Documents

Publication Publication Date Title
CN111601799B (zh) 作为Il-17调节剂的稠合咪唑衍生物
AU2016304408B2 (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitors
AU2018270685C1 (en) Novel compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same
US10077243B2 (en) Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
TWI829676B (zh) 噁二唑暫時受體電位通道抑制劑
JP5432846B2 (ja) β３アドレナリン受容体アゴニストとしてのヒドロキシメチルピロリジン
JP2026509484A (ja) Ｋｒａｓモジュレーターおよびその使用
AU2012258618B2 (en) Metabotropic glutamate receptors 5 modulators and methods of use thereof
CN108884066B (zh) 作为蛋白激酶抑制剂的2，3，5-取代的噻吩化合物
MX2011006997A (es) Compuestos de heteroarilo utiles como inhibidores de cinasa de factor recombinante activado (raf).
US20230138795A1 (en) Dopamine-b-hydroxylase inhibitors
IL324897A (en) Trem2 agonists
WO2017156177A1 (en) 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
TW202440529A (zh) Ｎａｍｐｔ調節劑
TW202204334A (zh) Menin抑制劑及治療癌症之使用方法
WO2003078441A1 (en) Aminomethyl-substituted thiazolobenzimidazole derivative
WO2026085458A1 (en) 3,4-dihydroquinoxalin-2(1h)-ones as bet bromodomain inhibitors and therapeutic methods using the same
CA3142348A1 (en) Dopamine-b-hydroxylase inhibitors
HK1258053B (en) Novel 2,3,5-substituted thiophene compound as protein kinase inhibitor
EA035237B1 (ru) ПРОИЗВОДНЫЕ ГЕТЕРОЦИКЛИЛАЛКИНОВ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ МЕТАБОТРОПНЫХ ГЛУТАМАТНЫХ РЕЦЕПТОРОВ 5-ГО ПОДТИПА (mGluR5)
OA18588A (en) 1,1,1-Trifluoro-3-Hydroxypropan-2-yl Carbamate Derivatives and 1,1,1-Trifluoro-4Hydroxybutan-2-yl Carbamate Derivatives as Magl Inhibitors.